MESOBLAST LTD
Business
MESOBLAST LTD is a commercial-stage biotechnology company that develops allogeneic (off-the-shelf) mesenchymal lineage cell therapies to treat severe inflammatory, cardiovascular, spine and other life‑threatening conditions. Its main products and candidates include Ryoncil® (remestemcel‑L‑rknd), an FDA‑approved MSC therapy for pediatric steroid‑refractory acute graft‑versus‑host disease, and rexlemestrocel‑L (Revascor®/MPC platform) in late‑stage development for heart failure and chronic low back pain. The company organizes around two core technology platforms (first‑generation MSC and second‑generation MPC products) and collaborates with licensees and manufacturing partners. Mesoblast distributes and develops products primarily through U.S. commercialization efforts and international partnerships covering Europe, Japan, China and other global markets.
Summary from filing dated 2025-08-29
Financials
Latest annual snapshot (FY2025, period end 2025-06-30). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | — |
| Total assets | $784.68M |
| Total liabilities | $187.24M |
| Stockholders' equity | — |
| Operating cash flow | — |